Torben Mourits‐Andersen

1.5k total citations · 1 hit paper
31 papers, 1.0k citations indexed

About

Torben Mourits‐Andersen is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Torben Mourits‐Andersen has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Hematology and 9 papers in Rheumatology. Recurrent topics in Torben Mourits‐Andersen's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Eosinophilic Disorders and Syndromes (5 papers). Torben Mourits‐Andersen is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Eosinophilic Disorders and Syndromes (5 papers). Torben Mourits‐Andersen collaborates with scholars based in Denmark, Sweden and Netherlands. Torben Mourits‐Andersen's co-authors include Ole Gadeberg, Michael Møller, Mikael Frederiksen, Lars Møller Pedersen, Zijun Y. Xu‐Monette, Tina Green, Carlo Visco, Ken H. Young, Attilio Orazi and Ronald S. Go and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Diabetes Care.

In The Last Decade

Torben Mourits‐Andersen

30 papers receiving 996 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

2012 481 citations Ole Gadeberg, Torben Mourits‐Andersen et al. profile →

Peers

Countries citing papers authored by Torben Mourits‐Andersen

Since Specialization

Citations

This map shows the geographic impact of Torben Mourits‐Andersen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torben Mourits‐Andersen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torben Mourits‐Andersen more than expected).

Fields of papers citing papers by Torben Mourits‐Andersen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Torben Mourits‐Andersen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torben Mourits‐Andersen. The network helps show where Torben Mourits‐Andersen may publish in the future.

Co-authorship network of co-authors of Torben Mourits‐Andersen

This figure shows the co-authorship network connecting the top 25 collaborators of Torben Mourits‐Andersen. A scholar is included among the top collaborators of Torben Mourits‐Andersen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Torben Mourits‐Andersen. Torben Mourits‐Andersen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of live music during chemotherapy in lymphoma patients: a randomized, controlled, multi-center trial 2019 ·Supportive Care in Cancer ·(unknown), Christoffer Johansen, Peter Vuust, Lisbeth Enggaard, (unknown), Torben Mourits‐Andersen, Peter de Nully Brown, Francesco d’Amore, Elisabeth Wreford Andersen, Niels Abildgaard, Jeppe Gram	27
2	High expression of PI3K core complex genes is associated with poor prognosis in chronic lymphocytic leukemia 2015 ·Leukemia Research ·(unknown), Thomas Kielsgaard Kristensen, Niels Abildgaard, Mads Thomassen, Mikael Frederiksen, Torben Mourits‐Andersen, Michael Møller	16
3	LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations 2015 ·European Journal Of Haematology ·(unknown), Thomas Kielsgaard Kristensen, Niels Abildgaard, Cristina Royo, Mikael Frederiksen, Torben Mourits‐Andersen, Elı́as Campo, Michael Møller	11
4	No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study 2015 ·Blood ·(unknown), Dennis Lund Hansen, Thomas Kielsgaard Kristensen, Karin de Stricker, Daniel El Fassi, Jesper Stentoft, (unknown), Mikael Frederiksen, Marianne Tang Severinsen, Ole Weis Bjerrum, Peter Möller, Torben Mourits‐Andersen, Ulrik Malthe Overgaard, Hans Carl Hasselbalch, Klaus Bendtzen, Thomas Stauffer Larsen	1
5	[Status and perspectives on chronic myeloproliferative neoplasm treatment]. 2015 ·PubMed ·(unknown), Morten Orebo Holmström, Caroline Hasselbalch Riley, Christen Lykkegaard Andersen, (unknown), (unknown), Mikael Frederiksen, (unknown), Ole Weis Bjerrum, (unknown), Torben Mourits‐Andersen, Hans Carl Hasselbalch, Thomas Stauffer Larsen	1
6	A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia 2013 ·British Journal of Haematology ·Henrik Birgens, Henrik Frederiksen, Hans Carl Hasselbalch, Inge Helleberg Rasmussen, Ove Juul Nielsen, Lars Kjeldsen, Herdis Larsen, Torben Mourits‐Andersen, Torben Plesner, Dorthe Rønnov‐Jessen, Hanne Vestergaard, Tobias Wirenfeldt Klausen, Claudia Schöllkopf	112
7	A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythemia 2012 ·Blood ·Christen Lykkegaard Andersen, Mary Frances McMullin, Elisabeth Ejerblad, Sonja Zweegman, Claire Harrison, (unknown), D. Bareford, Steven Knapper, Jan Samuelsson, Eva Löfvenberg, Olle Linder, Björn Andréasson, (unknown), Morten K. Jensen, Ole Weis Bjerrum, Hanne Vestergaard, Herdis Larsen, Tobias Wirenfeldt Klausen, Torben Mourits‐Andersen, Hans Carl Hasselbalch	3
8	R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group 2011 ·Annals of Oncology ·Anne Ortved Gang, Camilla Strøm, Mette Ølgod Pedersen, Francesco d’Amore, Lars Møller Pedersen, Anne Bukh, Bjarne Bach Pedersen, (unknown), Leif Spange Mortensen, Ole Gadeberg, Steen Ingeberg, Torben Mourits‐Andersen, (unknown), Peter de Nully Brown	52
9	Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML 2010 ·Cancer Genetics and Cytogenetics ·Birgitte Preiss, Olav J. Bergmann, (unknown), (unknown), (unknown), Ole Gadeberg, Torben Mourits‐Andersen, (unknown), Gitte Kerndrup	20
10	Lupus anticoagulant is significantly associated with inflammatory reactions in patients with suspected deep vein thrombosis 2007 ·Scandinavian Journal of Clinical and Laboratory Investigation ·Johannes Jakobsen Sidelmann, (unknown), Jørgen Gram, (unknown), Torben Mourits‐Andersen, (unknown), Anna‐Marie Bloch Münster, Jørgen Jespersen	16
11	Anagrelide treatment in 52 patients with chronic myeloproliferative diseases 2004 ·Clinical & Laboratory Haematology ·Elisabeth I Penninga, (unknown), Per Brinch Hansen, Nielsaage Tøffner Clausen, Torben Mourits‐Andersen, Olav Wendelboe Nielsen, Hans Carl Hasselbalch	21
12	A Phase II Trial of Pegylated Interferon α-2b in Polycythemia Vera and Essential Thrombocythemia. Clinical Responses, Effects on PRV-1 Expression and Impact on Quality of Life. 2004 ·Blood ·Jan Samuelsson, Hans Carl Hasselbalch, Øystein Bruserud, Heike L. Pahl, Mats Merup, Olle Linder, Yvonne Brandberg, (unknown), Magnus Björkholm, Waleed Ghanima, Claes Malm, Berit Markevärn, Torben Mourits‐Andersen, Peter Johansson, Lars Nilsson, Gunnar Birgegård	3
13	Cytogenetic findings in adult de novo acute myeloid leukaemia. A population‐based study of 303/337 patients 2003 ·British Journal of Haematology ·Birgitte Preiss, Gitte Kerndrup, Kai Gjerløff Schmidt, (unknown), (unknown), Ole Gadeberg, Torben Mourits‐Andersen, Niels T. Pedersen, (unknown)	27
14	Cytogenetic aberrations in adult acute lymphocytic leukemia 2001 ·Cancer Genetics and Cytogenetics ·(unknown), Gitte Kerndrup, (unknown), Torben Mourits‐Andersen, (unknown), (unknown), Kai Gjerløff Schmidt	9
15	Glycosylated haemoglobin (HbA_1c) in iron‐ and vitamin B12 deficiency 1990 ·Journal of Internal Medicine ·(unknown), (unknown), Torben Mourits‐Andersen, (unknown)	73
16	Plasma 6-keto-PGF1α, thromboxane B2 and PGE2 during diabetic ketoacidosis 1990 ·Prostaglandins Leukotrienes and Essential Fatty Acids ·Torben Mourits‐Andersen, Ingelise Jensen, Lene Kongsgaard Nielsen, G. L. Nielsen, J. Dyerberg, J. Ditzel	1
17	Plasma 6-keto-PGF1?, thromboxane B2 and PGE2 in Type 1 (insulin-dependent) diabetic patients during exercise 1987 ·Diabetologia ·Torben Mourits‐Andersen, Ingelise Jensen, (unknown), J. Ditzel, J. Dyerberg	12
18	[Megaloblastic anemia caused by malabsorption of vitamin B12 during long-term metformin therapy]. 1983 ·PubMed ·Torben Mourits‐Andersen, J Ditzel	3
19	Cigarette smoking shortens the bleeding time 1983 ·Thrombosis Research ·Troels Ring, Steen Dalby Kristensen, (unknown), Torben Mourits‐Andersen, Hans Madsen, Jørn Dyerberg	21
20	Changes in blood glucose, glycosylated hemoglobin and hemoglobin-oxygen affinity following meals in diabetic children 1981 ·European Journal of Pediatrics ·J. Ditzel, (unknown), Torben Mourits‐Andersen, Grete Østergaard, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact